Evidence map›Paper›PMID 32595613›Full record

ArticleFrontiers in microbiology2020

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition.

Wei Ye, Min Yao, Yangchao Dong, Chuantao Ye, Dan Wang, He Liu, Hongwei Ma, Hui Zhang, Libin Qi, Yuewu Yang and 7 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. An algal lectin griffithsin inhibits Hantaan virus infectionFrontiers in cellular and infection microbiology · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Wei YeDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Min YaoDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Yangchao DongDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Chuantao YeDepartment of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Dan WangSecond Affiliated Hospital, Xi'an Medical University, Xi'an, China.
He LiuDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Hongwei MaDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Hui ZhangDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Libin QiCadet Brigade, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Yuewu YangCadet Brigade, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Yuan WangDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Liang ZhangDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Linfeng ChengDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Xin LvDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Zhikai XuDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Yingfeng LeiDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Fanglin ZhangDepartment of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense

Indexed as

antiviralscRNAenterovirusEV71Remdesivir (GS-5734)vRNA

Identifiers

PMID32595613
PMCPMC7304253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.